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Objectives: To get insight in what criteria as presented in Health Technology Assessment (HTA) studies are important for decision makers in health care priority setting. 
Methods: We performed a discrete choice experiment (DCE) among Dutch health care professionals (policymakers, HTA experts, advanced HTA students). In 27 choice sets, we asked respondents to elect reimbursement of one of two different health care interventions, which represented unlabeled, curative treatments. Both treatments were incrementally compared to usual care. The results of the interventions were normal outputs of HTA studies with a societal perspective. Results were analysed using a multinomial logistic regression model.
Upon completion of the questionnaire we discussed the exercise with policymakers.    
Results: Severity of disease, costs per QALY gained, individual health gain, and the budget impact were the most decisive decision criteria. A program targeting more severe diseases increased the probability of reimbursement dramatically. Uncertainty related to cost-effectiveness was also important.  Respondents preferred health gains that include quality of life improvements over extension of life without improved quality of life. Savings in productivity costs were not crucial in decision making, although these are to be included in Dutch reimbursement dossiers for new drugs.  Regarding subgroups, we found that policymakers attached relatively more weight to disease severity than others but less to uncertainty. 
Conclusions:  Dutch policymakers and other health care professionals seem to have reasonably well articulated preferences: six of seven attributes were significant. Disease severity, budget impact, and cost-effectiveness were very important. The results are comparable to international studies, but reveal a larger set of important decision criteria.
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Health care policymakers decide on the diffusion of health care interventions and reimbursement of their costs on behalf of society, often relying on the results of economic evaluation studies to do so. Health Technology Assessment (HTA) is a fairly young science and, while the methodology of economic evaluation studies has gradually matured in the last decade, the systematic incorporation of economic evaluation results into policymaking is still too recent to fully understand how policymakers handle the multidimensional information they offer. Do decision makers take all dimensions reported in studies into account? Under what conditions do health gains or equity concerns outweigh other dimensions? What is the relative weight decision makers attach to productivity costs and uncertainty regarding the cost-effectiveness ratio? Answering such questions promotes transparency of the decision-making procedure and enables researchers to collect relevant decision-making data. 
	To our knowledge, only three articles have explored the explanation of past reimbursement decisions: two quantitative analyses focusing on guidance produced by NICE in the UK (5,6) and one qualitative study of Dutch reimbursement decisions (12). Each confirmed that cost-effectiveness is neither the only nor the dominant concern. Cost-effectiveness, clinical evidence, uncertainty, budget impact, the burden of disease and technology type explained NICE’s funding decisions better than cost-effectiveness alone (5,6). Pronk and Bonsel studied Dutch drug reimbursement decisions during the pre-compulsory pharmacoeconomic dossier period of 1999-2002 and concluded that budget impact, therapeutic value, and burden of disease were prominent criteria (12). 
	These studies are revealed-preference analyses, suggesting high validity. A limitation is that not all (potentially) influential decision-making factors can be studied because data available for current analysis derive from historical case characteristics. To enable prediction of future decisions, a wider range of concerns may need to be studied. This calls for stated-preference data. 
 		Our study builds on existing preference studies among policymakers or the general public (1;2;3;7;8;14;15), exploring hypothetical decisions in a Dutch policymaking context, which differs from other countries in that, since 2001, policy documents about reimbursement decisions have promoted the idea of varying the cost-effectiveness threshold with disease severity (4). A definition of disease severity was put forward to foster clarity (16). This policy model responded to the observation that policymakers were unable to fix a CE threshold. It would be interesting to see if this model held in practice and to identify the criteria that lay next to cost-effectiveness and disease severity. 
	We shed light on this matter by asking policymakers and other health care professionals to make choices between health care programs with divergent economic evaluation results. Our research questions are: (1) What criteria are important for respondents in health care priority setting? (2) To what extent do respondents make tradeoffs between these criteria? (3) 	Do our respondents take a societal perspective, as advocated in the literature?  For example, economic theory would exclude budget impact as a decision criterion (a dollar is a dollar).





In 27 choice sets, we asked respondents to elect reimbursement of one of two different health care interventions, A or B, which represented unlabeled, curative treatments (e.g. a new medicine or type of surgery). (Table 2 presents an example of the choice sets.) Both treatments were incrementally compared to usual care. The results of the interventions were normal outputs of economic evaluation studies with a societal perspective. Health care costs, other costs, and health effects in both the short and long runs were taken into account in the cost-effectiveness ratio. 
	The hypothetical treatments targeted patient groups most common to receiving treatments: males and females aged 50 to 75. This was motivated by our limited sample size and the desire to produce results that were meaningful in practice. We used a forced-choice design and, because respondents could not opt out, it provided information on many choice situations. 

Attributes and levels
A large number of possible attributes of interventions are mentioned in the literature and may be relevant to decision making (1;3;15). We discussed many of them with five experienced HTA researchers at length before selecting the seven shown in table 1. 
[Table 1 about here]
Attributes such as the amount of health gained and cost-effectiveness are key ingredients of any economic evaluation study. Disease severity (linked with equity concerns) has often been demonstrated to be a major consideration and was important to test in the Dutch context (3;8;16).  Savings in productivity costs were included, since Dutch guidelines for economic evaluation studies of new drugs require them. Budget impact is not standard output of economic evaluation studies, but it appears that policymakers often consider it (11). Including the composition of health gained (extension and/or improved quality of life (QoL)) was an outcome of the HTA researchers’ focus group. We also included uncertainty regarding cost-effectiveness. Uncertainty measures are increasingly standard research outputs, but we lack firm evidence on their use and whether they are appreciated by policymakers. With respect to health, Al has suggested considering decision makers’ risk attitudes (2).
	The attributes were of such nature that we could freely decide on their intensity and range of values. We chose to use three levels per attribute: low, intermediate, and high. We used more than two levels to allow for identification of non-linear attribute weights, and fewer than four levels to remain within the study constraints of a small sample. We decided on the attributes’ range of values pursuant to communications with and documents of relevant parties. The budget impact attribute (or additional annual medical costs) was given a minimum of €10 million (instead of 0 million), as most interventions incur additional costs. The top level, €50 million, is considered a very serious budget impact by Dutch policymakers. The range for the incremental cost-effectiveness ratio was inspired by the recent Dutch Health Council report that suggests €80,000 as a maximum paid for an additional QALY in case of an intervention for patients with a high disease severity (4).  The disease severity of the patient before treatment was explained using the following examples: a low disease severity is, e.g.,  eczema or non chronic, mild low back pain (with an estimated quality of life score of 0.94 on a scale of 0-1); a moderate disease severity is, e.g., heart failure or moderate rheumatoid arthritis (estimated quality of life score 0.65); a high disease severity is e.g., progressive multiple sclerosis (estimated quality of life score 0.33). 
	We carried out a pilot study with 10 HTA researchers, which resulted in editing the DCE layout and changing attribute levels for productivity savings and the cost-effectiveness ratio.  For an example of a complete choice set, see table 2.
					[table 2 about here]

Experimental design and regression model




We were interested in the respondents’ risk attitude towards health affects and health care costs. Hence, for one specific choice situation we asked whether the respondents preferred the situation in which (a) all uncertainty is related to health effects, (b) all uncertainty results from costs, or (c) they were indifferent.


Follow-up focus group discussion
Upon completion of the questionnaire we discussed the exercise with policymakers (members of the Ministry of Health, Department of Pharmaceutical Care; the Health Care Insurance Board; the Council for Public Health and Health Care). Issues included the exercise as a whole, attributes and levels, possible choice strategies, and the most difficult choice situations. 

Respondents
The DCE questionnaire was administered to 66 respondents during the months of 2007 through March 2008. All respondents were familiar with economic evaluation studies; all were given oral and written questionnaire instructions. About 40 percent were policymakers, deciding or advising on health insurance packages, pharmaceutical reimbursement, or general matters concerning allocation of health care funds and governance of health care (table 2). Since the group of people directly involved in the decision making process is small in practice, 60% of our sample consisted of other people having relevant knowledge of the decision making process. One-third comprised master students in health economics who had finished a course in HTA studies. About one-fifth of the respondents was engaged in performing HTA studies (see table 3). We tested for heterogeneity in preferences between subgroups of respondents by including interaction terms between the subgroup and each of the attributes. 







For one of the 27 choice sets, program A dominated program B with respect to all but one of the seven attributes. The exception was composition of the health gain, whose preferred level cannot be indicated beforehand. All sixty-six respondents preferred program A, which adds to the validity of the study. 

Regression results
The regression model’s explanatory power is quite satisfactory for a DCE (r-square= 0.307) (supplementary table 1). The observed sign for each coefficient was as expected: an intervention with a higher budget impact, higher cost per QALY, and more uncertainty was less likely to be preferred, whereas disease severity and the amount of individual health gain were positively linked to the probability of choosing the intervention. All attributes were significant (p<0.01) except for productivity savings (p=0.10). The positive sign for the composition of health gain indicates that respondents preferred health gains that include quality of life improvements over  extension of life without improved quality of life. 
	The only interaction term that was nearly statistically significant (p=0.06) was that between budget impact and cost-effectiveness. It was positive but small, thus tapering the negative effect of budget impact and the cost-effectiveness ratio. 
	The relative importance of each attribute in decision making varies. For example,  if an intervention costs an extra €10 million per year, its average probability of being preferred decreases by 16.6%.  (see the incremental effects in supplementary table 1). The results indicate that a one-level change in disease severity or cost-effectiveness has a very serious impact, changing the probability of choosing the program by 40%. The change in the amount of health gained per person was 20%. The impact of the other four attributes was smaller but not negligible. For example, a 10% rise in uncertainty resulted in a 9.8% decrease of choice probability. 
	Table 4 displays the effects of the observed attribute weights on attractiveness of a variety of hypothetical treatments. We compiled six scenarios representing archetypal cases. Scenario 1 set attributes at their most preferred levels; scenario 2 had “middle of the road” levels; scenario 3 was a typical worst case. Scenarios 4, 5 and 6 were added to illustrate the effects of budget impact and disease severity, where only one of each scenario’s attributes was not set at mid-level. Scenario 4 had a lowest-cost level; scenarios 5 and 6 had low and high disease severities, respectively. Table 4 shows the probability of one scenario being chosen over other another as predicted by the regression model, given the set of alternatives presented to the respondents. The scenarios’ attractiveness clearly varied. Disease severity affected the acceptance rate enormously (scenarios 1, 5, 6). The budget impact was also essential (scenario 4). 
[Table 4 about here]
	It was surprising that respondents (especially HTA students) preferred health gains that were accompanied with quality of life improvements over extension of life. Does this finding threaten the standard QALY model? Perhaps not. By definition, extension of life occurs as a health benefit in the distant future (especially for younger students), which might be discounted more than a quality of life gain occurring in the near future.

Subgroups compared
We also tested for significant differences in the weights of the attributes between respondent subgroups. These subgroup models had about the same explanatory power as the overall model.  The selection of statistically significant attributes was identical for all subgroups. However, for some attributes, subgroups appeared to have somewhat different weights, (see also supplementary table 2). 
	The policymakers attached relatively more weight to disease severity than others. HTA students showed a weaker, but still substantial, preference for disease severity.  Policymakers considered uncertainty related to cost-effectiveness, but less than others. As expected, for HTA experts uncertainty was relatively more important, as they have put it on the agenda. The HTA experts also attached somewhat more weight to cost-effectiveness but less to the magnitude of individual health gains. To our surprise HTA experts weighted productivity savings less than the other respondents, but it should be noted that this attribute is the only non significant one for the total group of respondents. 








The DCE was designed to explore tradeoffs between the various attributes. Some policymakers indeed tried to find an optimal balance on all criteria; some used simpler decision rules. All policymakers felt that the DCE was a valuable exercise, but added that cases in reality are often more complex and multi-dimensional. This confirms Lancsar’s findings (10). 
	Many policymakers felt that disease severity was their primary concern. Willingness to pay for treatments for minor ailments was rather limited. For some, disease severity and QALY gain dominated their decisions. Many felt that the most difficult choice sets were between moderate and high disease severity. Two stressed the importance of the composition of the health gain. 
	The policymakers also made statements about information they felt was missing: 
	The number of patients covered by the proposed health care interventions; 
	The health care costs per person; 
	The distribution of health gains by socio-economic status; 
	The budget impact of the intervention vis-à-vis the total health care budget; 
	Information on risk behaviour related to disease. 









The analysis in this paper clearly revealed what criteria stemming from HTA studies are most important for reimbursement decisions of medical treatments and to what extent tradeoffs are made. Severity of disease, costs per QALY gained, individual health gain, and the budget impact were the most decisive attributes. A program targeting more severe diseases increased the probability of reimbursement dramatically. Uncertainty related to cost-effectiveness was also important.  Respondents preferred health gains that include quality of life improvements over extension of life without improved quality of life.  For policy makers and the other health professionals the same set of attributes was important, but policy makers attached somewhat more weight to disease severity and less to uncertainty.
	According to the results, the respondents’ underlying optimisation function seemed to contain elements that were both utilitarian (preferring more health effects and less costs) and egalitarian (preferring a more equitable distribution of health) (13). 
	Our DCE had a comparatively small sample because we were limited to Dutch health care respondents familiar with the results of HTA studies. Our objective, however, was not to collect detailed choices for allocation decisions of specific health services, but rather to glean the relevance of attributes in the decision making process and the tradeoffs made by respondents.  Further study with a larger, preferably international, sample and further variation in attributes and levels should be conducted to verify the robustness of our results.  In addition, comparison of the results with new material on actual reimbursement decisions would be worthwhile. 

	Several other studies have been done following a stated-preference design, polling the decisions of policymakers and/or the public (1;2;3;7;8;14;15). Five studies used a conjoint analysis or discrete choice experiment (DCE) framework. Baltussen’s (3) DCE involved Nepalese policymakers’ and health professionals’ choices for a public health priority setting. He found that the Nepalese preferred interventions that (a) targeted large sets of middle-aged groups and severe diseases; (b) had significant individual health benefits; (c) led to poverty reduction; and (d) were cost-effective.
	Schwappach (15) investigated the reliability of an internet-based survey to elicit preferences for priority setting of hypothetical treatment programs.  Schwappach reported a preference for programs that targeted younger age groups and common diseases, had significant individual health benefits, and were below average in cost.
	Green (7) analysed health program choices of the UK general public. Using less complex qualitative attributes (e.g., very good, fairly good, fairly poor, very poor cost-effectiveness), he showed that DCE was feasible and valid for the general public and that all four attributes – health improvement, cost-effectiveness, disease severity, and the availability of other treatments – were important.
	Gyrd-Hansen (8) investigated the Danish public’s view on the tradeoff between the amount and the distribution of health gains secondary to interventions:  the Danish public gave priority to those in a more severe health state.
	Ratcliffe et al. (14) studied the views of UK National Health Service decision makers and care providers using four attributes: health benefits (in QALYS), the share of QALYs gained for the worst off, waiting time for treatment, and travel distance to care facilities. All were important, although health benefits dominated. Because costs and cost-effectiveness were not used as attributes, it is difficult to draw direct conclusions for allocation decisions.  
	Although the results of  studies vary with context and research objects, one could say that our study largely confirms these results, but shows a larger set of important (quantitative) decision criteria, including their relative importance. 

	Do our Dutch respondents take a societal perspective, as advocated? Economic theory supports as attributes: cost-effectiveness, individual health gain, disease severity, and productivity savings. All these criteria were significant, except for productivity savings. Economic theory would exclude budget impact (a dollar is a dollar) as a criterion. In our study, budget impact is important, which corresponds with recent research (11). It may reflect that the normative content of economic theory is not upheld after all, or that decision makers face particular problems in its application.





We performed a discrete choice experiment (and focus group discussion) among Dutch policymakers and other health professionals in order to identify the criteria stemming from HTA studies that are most relevant in reimbursement decisions of medical interventions and what tradeoffs emerge between them. The analysis revealed that all attributes were very significant except for the savings in productivity costs. Severity of disease, costs per QALY gained, individual health gain, and the budget impact were the most decisive attributes. A program targeting more severe diseases increased the probability of reimbursement dramatically.  For policy makers and the other health professionals the same set of attributes was important, but policy makers attached somewhat more weight to disease severity and less to uncertainty. Our study largely confirms results of other studies, but shows a larger set of important (quantitative) decision criteria, including their relative importance.
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Table 1 Attributes and levels of the DCE
Attribute	Levels
National additional medical costs per year (budget impact)	10, 20, 50 (million euros)
National saving in costs of absence from work per year	0, 2, 4 (million euros) 
Disease severity (before treatment)	Low, moderate, high
Incremental cost-effectiveness ratio of the intervention	15,000; 45,000; 90,000 (euros per QALY)
The number of QALYs gained per patient	0.5, 2, 4 (QALYs) 
The composition of the health gain	100% longer life, 100% improved QoL, 50% of each




Table 2 Example of a choice set 

 	Treament A	Treatment B
Additional national medical costs per year 	20 million euro	50 million euro
National saving in costs of absence from work per year	 0 million euro	 2 million euro
Disease severity of the patient before treatment	Moderate	High
Incremental cost per QALY	45,000 euro	90,000 euro
Number of QALYs gained per patient	2 QALYs	4 QALYs
Composition of the health gain 	50% longer life50% quality of life 	100% quality of life 




















Table 4. Predicted probability of acceptance of choice situations (scenarios)
Attribute	Scenario 1Best	Scenario 2Mid	Scenario 3Worst	Scenario 4Mid cheap	Scenario 5Mid low*	Scenario 6Mid high*
Acceptance %	99.7%	48.2%	0.03%	64.4%	15.9%	82.1%
Medical cost (million euros)	10	20	50	10	20	20
Productivity savings (million euros)	4	2	0	2	2	2
Disease severity 	high	moderate	Low	Moderate	low	high
Cost per Qaly (euros)	15,000	45,000	90,000	45,000	45,000	45,000
Health gain (QALYs)	4	2	0.5	2	2	2
Composition of health gain	Qol	50/50	Longer life	50/50	50/50	50/50
Uncertainty (%)	10%	20%	30%	20%	20%	20%





Supplementary Table 1. Marginal effects: incremental effect of a change of attributes by one level on the probability of scenario choice (derived from marginal effects) as derived from the logit model
Attribute	Marginal effect	T-value	Incremental effect
Budget impact (mln euro)	-0.01664	-6.48	-  16.6%
Productivity savings (mln euro)	0.01473	1.29	+  3.5%
Disease severity 	0.39892   	13.63	+ 39.9%
Cost per Qaly (euro)	-0.000014	-10.07	- 42.6%
Health gain (QALYs)	 0.14806   	9.29	+ 22.2%
Composition health gain	 0.09447   	4.32	+  9.4%
Uncertainty (%)	-0.00976	-4.46	-  9.8%
Budget impact * cost-effectiveness	8.95*10-8	1.81	+ 0,9%




Supplementary Table 2. Marginal effects of interaction terms per attribute, per subgroup as compared to all other respondents.
Attribute	Policy makers	HTA experts	Advanced HTA students
Budget impact (mln euro)	            0,0026	-0,006	-0,0092
Productivity savings (mln euro)	0,0194	-0,042*	0,0116
Disease severity 	0,1211**	0,038	-0,1157**









Explanation of attributes for respondents.
The treatments as described have the following elements:
	The national additional medical costs per year when the treatment is introduced on a national scale instead of usual care; 
	The national saving in costs of absence from work per year when the treatment is introduced on a national scale instead of usual care; 
	The disease severity of the patient before treatment: a low disease severity is, e.g.,  eczema or non chronic, mild low back pain (with an estimated quality of life score of 0.94 on a scale of 0-1); a moderate disease severity is, e.g., heart failure or moderate rheumatoid arthritis (estimated quality of life score 0.65); a high disease severity is e.g., progressive multiple sclerosis (estimated quality of life score 0.33);
	The incremental cost-effectiveness ratio of the new treatment compared to usual care in euros per QALY (Quality Adjusted Life Year) gained;
	The amount of the health gain in number of QALYs gained per patient during the rest of their lives as a result of the new treatment;
	The composition of the health gain: (a) a longer life, (b) an improvement in health status, (c) a combination of a and b;
	The degree of uncertainty with respect to the mentioned cost-effectiveness ratio. What is the probability that after introduction the costs per QALY will be much higher? In economic evaluation studies, this type of uncertainty is often depicted with an acceptability curve. The uncertainty may derive from costs, health effects, or both. We will present a probability that the costs per QALY will be at least doubled as compared to the cost-effectiveness ratio mentioned above. 
Please indicate which treatment (compared to usual care) you would prefer to reimburse or introduce on a national scale: A or B.

Experimental design 
Our design of 27 pair wise comparisons of two hypothetical treatments was meant to be orthogonal, based on an orthogonal main effects plan from the catalogue of Kocur (9), using department plan 20b (master plan 8), which allowed estimating the main effects and, for three of the attributes (budget impact, cost-effectiveness, uncertainty), orthogonal 2-factor interactions. 
Each alternative defined on basis of the OMEP was paired to an alternative in such a way that the minimal overlap criterion was satisfied. We adapted the choice set in one respect: we disallowed the seemingly implausible combination of a low disease severity (pre-treatment) with the highest number of Qalys (4) gained per patient. 
	The resulting design was not completely orthogonal, but 94% efficient (17). Prior to our study, we inspected the correlation matrix of the seven attributes: the mean of the absolute values of the correlation coefficients was 0.0416; the maximum value was 0.21. On basis of these figures we did not expect estimation problems related to multicollinearity. 

Regression model
	Respondent choices were analysed using a multinomial logistic regression model. Given that all respondents had the same choice sets, we conditioned on the set rather than individual respondent choice. We tested for incidental parameter bias by comparing the obtained marginal rates of substitution from two models: a conditional or fixed-effect logistic regression and a dummy variable logistic regression with a dummy for each choice set, minus one for the default choice set. Both models presented comparable results in terms of policy implications. This study’s results are based on the dummy variable model as it allowed estimating marginal effects. 
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